Nobel prize nominee part of new Singapore eDevelopment team to research Alzheimer’s, cancer

SINGAPORE (March 13): Singapore eDevelopment (SeD) has named senior members of its new biomedical management division, SeD BioMedical, that includes two-time Nobel Prize nominee Daryl Thompson.

Thompson, who has been appointed director of scientific initiatives at SeD BioMedical, will spearhead advanced research to develop a broad-spectrum therapeutic platform to address emerging pandemics such as Alzheimer’s, diabetes, cancer, drug-resistant viruses and antibiotic-resistant bacteria.

He is part of a six-member management team that also includes Rajen Manicka as CEO, Scott Truesdell as research coordinator, Kent Lau Keng Yap who will specialise in R&D commercialisation, plus two other names that have yet been revealed.

---

Related Stories

• This medical breakthrough has its origins in Singapore
• How do we fix Bernanke's fixes? That's for a future Nobel
• MPM Capital raises US$850 mil for cancer fund, with US$650 million from UBS

---